MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-28-2026
NeoGenomics Total Liabilities 2011-2026 | NEO
Annual Total Liabilities NeoGenomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 523 M | 736 M | 740 M | 742 M | 762 M | 294 M | 202 M | 185 M | 138 M | 151 M | 130 M | 20.7 M | 18.2 M | 20.9 M | 14.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 762 M | 14.1 M | 312 M |
Quarterly Total Liabilities NeoGenomics
| 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 518 M | 523 M | 540 M | 713 M | 736 M | 733 M | 727 M | 717 M | 740 M | 731 M | 739 M | 735 M | 742 M | 743 M | 749 M | 755 M | 762 M | 769 M | 748 M | 651 M | 294 M | 294 M | 294 M | 294 M | 202 M | 202 M | 202 M | 202 M | 185 M | 185 M | 185 M | 185 M | 140 M | 140 M | 140 M | 140 M | 151 M | 151 M | 151 M | 151 M | 113 M | 113 M | 113 M | 113 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 769 M | 14.1 M | 312 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
108 M | $ 20.5 | 2.35 % | $ 594 M |  USA |
 |
Fulgent Genetics
FLGT
|
90.8 M | $ 17.26 | 5.18 % | $ 522 M | USA |
 |
Guardant Health
GH
|
2.11 B | $ 117.73 | 2.27 % | $ 14.8 B | USA |
 |
ICON Public Limited Company
ICLR
|
7.35 B | $ 116.4 | 1.14 % | $ 9.6 B |  Irlanda |
 |
Agilent Technologies
A
|
5.32 B | $ 114.6 | 0.76 % | $ 34.8 B | USA |
 |
Illumina
ILMN
|
2.7 B | $ 144.78 | 2.02 % | $ 23 B | USA |
 |
Celcuity
CELC
|
366 M | $ 141.5 | 0.83 % | $ 6.62 B | USA |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 3.77 | 57.74 % | $ 5.01 M | USA |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
110 M | $ 21.63 | 2.25 % | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 94.36 | -1.8 % | $ 6.37 B | USA |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 1.8 | - | $ 7.96 M | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 428.74 | 1.63 % | $ 12.4 B | USA |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 089.93 | 0.63 % | $ 22.5 B |  Schweiz |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Personalis
PSNL
|
73 M | $ 8.31 | 4.47 % | $ 742 M | USA |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 159.19 | 1.99 % | $ 7.89 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
121 M | $ 19.07 | -0.99 % | $ 427 M | USA |
 |
Natera
NTRA
|
689 M | $ 201.96 | -1.44 % | $ 19.9 B | USA |
 |
Myriad Genetics
MYGN
|
339 M | $ 3.88 | 1.71 % | $ 359 M | USA |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
16 B | $ 27.19 | 1.72 % | $ 25.8 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
169 M | $ 59.01 | 9.97 % | $ 3.53 B | USA |
 |
Senseonics Holdings
SENS
|
65.2 M | $ 6.07 | 6.3 % | $ 253 M | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
114 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
1.84 M | $ 2.41 | 2.55 % | $ 5.54 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 255.56 | -0.68 % | $ 21.3 B | USA |
 |
Waters Corporation
WAT
|
2.52 B | $ 340.75 | -0.14 % | $ 20.3 B | USA |
 |
Thermo Fisher Scientific
TMO
|
28.7 B | $ 449.36 | -0.5 % | $ 169 B | USA |
 |
Trinity Biotech plc
TRIB
|
138 M | $ 0.64 | 5.08 % | $ 230 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Exagen
XGN
|
40.6 M | $ 4.24 | 10.68 % | $ 91.4 M | USA |
 |
Neogen Corporation
NEOG
|
1.37 B | $ 8.85 | 0.23 % | $ 1.92 B | USA |